Isotopia Ltd is pleased to announce
that it has begun a collaboration with Molecular Targeting Technologies, Inc. (MTTI),
a clinical stage biopharmaceutical company, for the supply of the medical radioisotope
no-carrier-added 177Lu (n.c.a. 177Lu) to support clinical development of its targeted
Molecular Targeting Technologies, Inc. (MTTI) has received an exclusive worldwide
license from the National Institutes of Health to commercialize targeted
radiotherapeutics covered by their Evans Blue (EB) platform technology patents.
177LuEBTATE, which targets somatostatin receptors type 2 (SSTR2) in a variety of
neuroendocrine tumors (NETs), and 177Lu-EBRGD for integrin expressing cancers in
Glioblastoma multiforme (GBM) and Non-Small Cell Lung cancer (NSCLC), are the
first products in development. In this breakthrough, EB is affixed to the targeting
peptide radiopharmaceutical. That combination binds reversibly to circulating serum
albumin, enhancing radiotherapeutic circulation half-life and delivering higher
accumulation to targeted tumors.
177Lu is a beta-emitting radiopharmaceutical precursor with a half-life of 6.7 days and
a maximum energy of 0.5 MeV, corresponding to a maximum soft-tissue penetration
of approximately 1 mm from its binding site.
177Lu is used in Precision Oncology for Targeted Radionuclide Therapy.
It, precisely, destroys the tumor when bound to disease-specific, targeting therapeutics.
Isotopia has developed a unique, stable, consistent and reliable GMP method to produce
a highly pure form of 177Lu. n.c.a. Isotopia’s 177Lu contains no metastable 177mLu,
eliminating cost intensive clinical waste management.
Isotopia’s CEO Dr. Eli Shalom stated, “Our strategy is to be partner to every leading
pharmaceutical company developing Lu-177 n.c.a based products, supporting them
from clinical trials through commercial sale.
We are committed to produce 52 weeks
per year, ensuring supply through long-term contracts. We’re patient-centric. Our two
years of robust, reliable and flawless production enhances patient confidence.
MTTI is a remarkable company which advances their vision for the development of new
radiotherapeutics and Isotopia is proud to be part of it.”
Dr. Chris Pak, MTTI’s President & CEO said, ” We’ve secured a timely and sustainable
supply of a key therapeutic ingredient needed for the development and launch of our
lead asset 177Lu-EBTATE and other EB platform technologies.
We are excited to start this collaboration and build what promises to be a great relationship with a reliable and
trusted radioisotope supply partner like Isotopia for the purest form of 177Lu-177 n.c.a.”
Molecular Targeting Technologies, Inc. (West Chester, PA, USA) is a privately held,
rapidly growing, well financed, clinical stage biotech developing targeted
radiotherapeutics and diagnostics for rare cancers. We are committed to building value
by acquiring and translating innovative imaging, radiopharmaceutical and theranostic
assets to improve human health, reduce healthcare costs and reward stakeholders.
MTTI expects to be orchestrating multiple clinical trials in 2021.
Contact: Chris Pak,
Tel: (610) 738-7938
Isotopia is a collaboration between The Metrontario Group and
Israeli’s leading scientists in the field of radiopharmaceuticals. The Isotopia
development team is a multidisciplinary team consisting of nuclear pharmacists,
radiochemists, nuclear engineers and physicists.
The experienced Isotopia team, together with its radio-nuclear pharmacy, cyclotron
facility, 177Lu production site and sterile manufacturing, are a well-established
platform for development. Isotopia creates collaborations between the scientific and
medical community to further develop and experiment with new markers for imaging
applications and molecular therapy.